CMV eVLP: Phase I started

VBI began a placebo-controlled, Canadian Phase I trial to evaluate unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A given at months 0, 2 and 6 in about 125 CMV-seronegative healthy adult vol...